Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Boget

Physician Assistant, Medical Swansea, IL Physician Assistant

NPI 1619083102 CMS profile 10644582

4948 Benchmark Centre Dr, Swansea, IL 62226

Open in the dashboard

General payments

$9,446

550 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Boget of Swansea, IL is reported in the CMS Open Payments database as having received $9,446 across 550 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,417 234
2024 General $4,156 220
2023 General $1,086 60
2022 General $768 35
2021 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Boget
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lisa Boget were reported at $3,417. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lisa Boget Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $19 $156 $41–$563 $132
2022 $768 $185 $55–$649 $149
2023 $1,086 $199 $58–$717 $160
2024 $4,156 $206 $62–$740 $164
2025 $3,417 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,241 84 payments
  2. Sun Pharmaceutical Industries Inc. $1,160 58 payments
  3. LEO Pharma Inc. $939 29 payments
  4. Janssen Biotech, Inc. $751 50 payments
  5. Lilly USA, LLC $630 38 payments
  6. E.R. Squibb & Sons, L.L.C. $591 62 payments
  7. Pfizer Inc. $533 24 payments
  8. Amgen Inc. $524 26 payments
  9. Novartis Pharmaceuticals Corporation $523 23 payments
  10. Dermavant Sciences, Inc. $515 43 payments
  11. Other $2,039 113 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,771 542 payments
  2. Education $675 8 payments
Products named General payments · program years 2021–2025
  1. ADBRY $837 25 payments
  2. RINVOQ $729 46 payments
  3. ILUMYA $701 45 payments
  4. TREMFYA $649 44 payments
  5. SOTYKTU $575 61 payments
  6. VTAMA $561 50 payments
  7. DUPIXENT $546 17 payments
  8. Otezla $524 26 payments
  9. TALTZ $509 31 payments
  10. OPZELURA $456 23 payments
  11. Other $4,526 261 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

943

Median for Physician Assistant: 241

Drug cost

$857,364

Median for Physician Assistant: $4,110

Branded share of claims

17.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 14 $296,592
Dupixent Pen Dupilumab Brand 73 $272,207
Humira(Cf) Pen Adalimumab Brand 18 $119,374
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $96,881
Otezla Apremilast Brand 11 $49,784
Ketoconazole Generic 262 $4,220
Tacrolimus Generic 35 $4,038
Clobetasol Propionate Generic 76 $3,837
Doxycycline Hyclate Generic 92 $2,775
Fluorouracil Generic 32 $1,901

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$70,388

Of which drugs: $4,159

Medicare patients

543

Average age 74

Services billed

4,982

316 women, 227 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 48%
Ischemic heart disease 28%
Diabetes 22%
Chronic kidney disease 18%
Atrial fibrillation 13%
Cancer 13%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 16 3,200 $4,147

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$442 — —
ADBRY
$413 — —
TREMFYA
$370 — —
SOTYKTU
$362 — —
VTAMA
$342 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

550 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record